Multicentre, Double-blind, Randomised, Placebo-controlled Study in Four Parallel Groups of PD Patients Treated With Standard-release Levodopa/Carbidopa 100/25 mg (Sinemet) or Levodopa/Benserazide 100/25 mg (Madopar/Restex) and With Motor Fluctuations ("Wearing-off" Phenomenon)

Trial Profile

Multicentre, Double-blind, Randomised, Placebo-controlled Study in Four Parallel Groups of PD Patients Treated With Standard-release Levodopa/Carbidopa 100/25 mg (Sinemet) or Levodopa/Benserazide 100/25 mg (Madopar/Restex) and With Motor Fluctuations ("Wearing-off" Phenomenon)

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2015

At a glance

  • Drugs Opicapone (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Bial
  • Most Recent Events

    • 07 Jan 2015 According to the ClinicalTrials.gov record the primary endpoint changed to Cmax and Tmax.
    • 20 Jun 2013 Results presented at the 17th International Congress of Parkinson's Disease and Movement Disorders.
    • 12 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top